Scarica l'app Stockscreener
28.19
0.08%
-0.0012
Precedente Chiudi:
$28.19
Aprire:
$28.14
Volume 24 ore:
396.77K
Relative Volume:
0.36
Capitalizzazione di mercato:
$1.65B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.4814
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
-6.05%
1M Prestazione:
+6.01%
6M Prestazione:
-21.78%
1 anno Prestazione:
-17.03%
Intervallo 1D:
$27.47
$28.38
Intervallo di 1 settimana:
$27.47
$30.52
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.18 | 1.65B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.69 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.88 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.44 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
290.22 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO (2026-03-04) - Seeking Alpha
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales - Stock Titan
AGIOS (NASDAQ: AGIO) CCO reports new equity awards and tax-driven share sales - Stock Titan
Agios (AGIO) accounting officer sells shares to cover RSU tax withholding - Stock Titan
Agios (NASDAQ: AGIO) executive granted 14,000 RSUs and 52,000 options - Stock Titan
AGIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights A - GuruFocus
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - MarketBeat
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
AGIO (Nasdaq: AGIO) reports RSU vesting and Brian Goff sale disclosure - Stock Titan
AGIO (NASDAQ: AGIO) insider resale notice for 5,218 shares on 03/02/2026 - Stock Titan
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale notice: 5,035 AGIO shares tied to RSU vesting (NASDAQ: AGIO) - Stock Titan
Insider sells and RSUs vest at AGIO (NASDAQ: AGIO) — 2,868 RSUs listed - Stock Titan
AGIO: Mitapivat’s thalassemia launch accelerates, with pipeline and regulatory catalysts ahead - TradingView
Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates - marketscreener.com
Agios Pharmaceuticals (AGIO) Gains UAE Approval for Pyrukynd - GuruFocus
Vanguard Group Inc. Sells 77,143 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - Bitget
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - The Manila Times
UAE approves only treatment option for adults with thalassemia - Stock Titan
Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Passes Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A 28.73% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (AGIO) - Stock Traders Daily
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates - MSN
BOOTHBAY FUND MANAGEMENT, LLC's Agios Pharmaceuticals Inc(AGIO) Holding History - GuruFocus
Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Why Agios Pharmaceuticals Inc. stock is popular among millennialsTrade Volume Summary & High Yield Stock Recommendations - mfd.ru
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North - openPR.com
Agios’ 2025 Loss, AQVESME Launch, and New Shelf Offering Might Change The Case For Investing In Agios Pharmaceuticals (AGIO) - Sahm
HC Wainwright Issues Positive Estimate for AGIO Earnings - MarketBeat
Is Agios Pharmaceuticals Inc. stock overvalued by current metricsLayoff News & Smart Swing Trading Alerts - mfd.ru
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress - Yahoo Finance
Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook - The Globe and Mail
Wall Street Zen Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios Pharmaceuticals Q4 2025 earnings preview - MSN
STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Brokers Offer Predictions for AGIO FY2030 Earnings - MarketBeat
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Goff Brian | Chief Executive Officer |
Mar 02 '26 |
Sale |
28.96 |
18,055 |
522,873 |
147,733 |
| Burns James William | Chief Legal Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
17,586 |
0 |
45,249 |
| Burns James William | Chief Legal Officer |
Mar 02 '26 |
Sale |
28.96 |
5,218 |
151,113 |
34,531 |
| Gheuens Sarah | Chief Medical Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
13,666 |
0 |
75,593 |
| Gheuens Sarah | Chief Medical Officer |
Mar 02 '26 |
Sale |
28.96 |
4,055 |
117,433 |
67,608 |
| Jones Cecilia | Chief Financial Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
16,969 |
0 |
50,901 |
| Jones Cecilia | Chief Financial Officer |
Mar 02 '26 |
Sale |
28.96 |
5,035 |
145,814 |
38,800 |
| Milanova Tsveta | Chief Commercial Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
9,666 |
0 |
42,778 |
| Milanova Tsveta | Chief Commercial Officer |
Mar 02 '26 |
Sale |
28.96 |
2,868 |
83,057 |
38,778 |
3.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):